AMEDISYS INC (AMED) Stock Fundamental Analysis
NASDAQ:AMED - Nasdaq - US0234361089 - Common Stock - Currency: USD
Overall AMED gets a fundamental rating of 5 out of 10. We evaluated AMED against 103 industry peers in the Health Care Providers & Services industry. While AMED has a great profitability rating, there are some minor concerns on its financial health. AMED has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
AMED had positive earnings in the past year.
In the past year AMED had a positive cash flow from operations.
Of the past 5 years AMED 4 years were profitable.
Each year in the past 5 years AMED had a positive operating cash flow.
1.2 Ratios
With a decent Return On Assets value of 4.11%, AMED is doing good in the industry, outperforming 73.79% of the companies in the same industry.
AMED's Return On Equity of 7.49% is fine compared to the rest of the industry. AMED outperforms 67.96% of its industry peers.
With an excellent Return On Invested Capital value of 10.15%, AMED belongs to the best of the industry, outperforming 81.55% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for AMED is in line with the industry average of 9.71%.
The last Return On Invested Capital (10.15%) for AMED is above the 3 year average (9.73%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.11% | ||
| ROE | 7.49% | ||
| ROIC | 10.15% |
ROA(3y)2.52%
ROA(5y)6.1%
ROE(3y)4.72%
ROE(5y)11.86%
ROIC(3y)9.73%
ROIC(5y)11.44%
1.3 Margins
With a decent Profit Margin value of 3.79%, AMED is doing good in the industry, outperforming 71.84% of the companies in the same industry.
AMED's Profit Margin has declined in the last couple of years.
The Operating Margin of AMED (9.17%) is better than 79.61% of its industry peers.
In the last couple of years the Operating Margin of AMED has remained more or less at the same level.
Looking at the Gross Margin, with a value of 43.37%, AMED is in the better half of the industry, outperforming 70.87% of the companies in the same industry.
In the last couple of years the Gross Margin of AMED has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.17% | ||
| PM (TTM) | 3.79% | ||
| GM | 43.37% |
OM growth 3Y-10.17%
OM growth 5Y-0.51%
PM growth 3Y-42.02%
PM growth 5Y-22.26%
GM growth 3Y-1.85%
GM growth 5Y1.03%
2. Health
2.1 Basic Checks
AMED has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
AMED has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, AMED has more shares outstanding
AMED has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.96 indicates that AMED is not in any danger for bankruptcy at the moment.
AMED's Altman-Z score of 3.96 is fine compared to the rest of the industry. AMED outperforms 73.79% of its industry peers.
AMED has a debt to FCF ratio of 1.69. This is a very positive value and a sign of high solvency as it would only need 1.69 years to pay back of all of its debts.
The Debt to FCF ratio of AMED (1.69) is better than 83.50% of its industry peers.
A Debt/Equity ratio of 0.28 indicates that AMED is not too dependend on debt financing.
AMED's Debt to Equity ratio of 0.28 is fine compared to the rest of the industry. AMED outperforms 64.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 1.69 | ||
| Altman-Z | 3.96 |
ROIC/WACC1.18
WACC8.63%
2.3 Liquidity
AMED has a Current Ratio of 1.29. This is a normal value and indicates that AMED is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.29, AMED is doing worse than 60.19% of the companies in the same industry.
A Quick Ratio of 1.29 indicates that AMED should not have too much problems paying its short term obligations.
AMED has a Quick ratio of 1.29. This is comparable to the rest of the industry: AMED outperforms 45.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.29 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 4.86% over the past year.
Measured over the past years, AMED shows a decrease in Earnings Per Share. The EPS has been decreasing by -0.46% on average per year.
The Revenue has been growing slightly by 5.34% in the past year.
The Revenue has been growing slightly by 3.73% on average over the past years.
EPS 1Y (TTM)4.86%
EPS 3Y-10.14%
EPS 5Y-0.46%
EPS Q2Q%21.36%
Revenue 1Y (TTM)5.34%
Revenue growth 3Y1.98%
Revenue growth 5Y3.73%
Sales Q2Q%4.09%
3.2 Future
Based on estimates for the next years, AMED will show a small growth in Earnings Per Share. The EPS will grow by 7.37% on average per year.
Based on estimates for the next years, AMED will show a small growth in Revenue. The Revenue will grow by 4.80% on average per year.
EPS Next Y12.8%
EPS Next 2Y11.02%
EPS Next 3Y7.37%
EPS Next 5YN/A
Revenue Next Year4.17%
Revenue Next 2Y4.71%
Revenue Next 3Y4.8%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 21.21 indicates a rather expensive valuation of AMED.
Compared to the rest of the industry, the Price/Earnings ratio of AMED indicates a somewhat cheap valuation: AMED is cheaper than 66.99% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of AMED to the average of the S&P500 Index (27.45), we can say AMED is valued slightly cheaper.
A Price/Forward Earnings ratio of 18.09 indicates a rather expensive valuation of AMED.
Based on the Price/Forward Earnings ratio, AMED is valued a bit cheaper than 65.05% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.90, AMED is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.21 | ||
| Fwd PE | 18.09 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AMED is valued a bit cheaper than 62.14% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, AMED is valued a bit cheaper than the industry average as 77.67% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.43 | ||
| EV/EBITDA | 11.61 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
AMED has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)1.66
PEG (5Y)N/A
EPS Next 2Y11.02%
EPS Next 3Y7.37%
5. Dividend
5.1 Amount
AMED does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
96.1
+0.14 (+0.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners93.07%
Inst Owner Change-1.69%
Ins Owners1.89%
Ins Owner Change6.08%
Market Cap3.15B
Analysts53.75
Price Target102.85 (7.02%)
Short Float %6.11%
Short Ratio5.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.99%
Min EPS beat(2)-10.15%
Max EPS beat(2)12.12%
EPS beat(4)2
Avg EPS beat(4)-1.2%
Min EPS beat(4)-15.99%
Max EPS beat(4)12.12%
EPS beat(8)3
Avg EPS beat(8)-0.55%
EPS beat(12)6
Avg EPS beat(12)2.46%
EPS beat(16)8
Avg EPS beat(16)2.78%
Revenue beat(2)0
Avg Revenue beat(2)-2.12%
Min Revenue beat(2)-2.2%
Max Revenue beat(2)-2.05%
Revenue beat(4)1
Avg Revenue beat(4)-1.53%
Min Revenue beat(4)-2.2%
Max Revenue beat(4)0.13%
Revenue beat(8)1
Avg Revenue beat(8)-1.99%
Revenue beat(12)1
Avg Revenue beat(12)-2.69%
Revenue beat(16)1
Avg Revenue beat(16)-2.79%
PT rev (1m)0%
PT rev (3m)3.55%
EPS NQ rev (1m)-0.8%
EPS NQ rev (3m)-1.24%
EPS NY rev (1m)0.03%
EPS NY rev (3m)0.32%
Revenue NQ rev (1m)-0.09%
Revenue NQ rev (3m)-0.36%
Revenue NY rev (1m)-0.48%
Revenue NY rev (3m)-0.95%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.21 | ||
| Fwd PE | 18.09 | ||
| P/S | 1.33 | ||
| P/FCF | 14.43 | ||
| P/OCF | 14.05 | ||
| P/B | 2.63 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.61 |
EPS(TTM)4.53
EY4.71%
EPS(NY)5.31
Fwd EY5.53%
FCF(TTM)6.66
FCFY6.93%
OCF(TTM)6.84
OCFY7.12%
SpS72.26
BVpS36.55
TBVpS-2.88
PEG (NY)1.66
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.11% | ||
| ROE | 7.49% | ||
| ROCE | 12.85% | ||
| ROIC | 10.15% | ||
| ROICexc | 12.2% | ||
| ROICexgc | 151.22% | ||
| OM | 9.17% | ||
| PM (TTM) | 3.79% | ||
| GM | 43.37% | ||
| FCFM | 9.22% |
ROA(3y)2.52%
ROA(5y)6.1%
ROE(3y)4.72%
ROE(5y)11.86%
ROIC(3y)9.73%
ROIC(5y)11.44%
ROICexc(3y)10.87%
ROICexc(5y)12.42%
ROICexgc(3y)283.58%
ROICexgc(5y)337.19%
ROCE(3y)12.32%
ROCE(5y)14.48%
ROICexcg growth 3Y57.65%
ROICexcg growth 5Y52.31%
ROICexc growth 3Y-5.72%
ROICexc growth 5Y-4.31%
OM growth 3Y-10.17%
OM growth 5Y-0.51%
PM growth 3Y-42.02%
PM growth 5Y-22.26%
GM growth 3Y-1.85%
GM growth 5Y1.03%
F-Score7
Asset Turnover1.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 1.69 | ||
| Debt/EBITDA | 1.2 | ||
| Cap/Depr | 9.64% | ||
| Cap/Sales | 0.25% | ||
| Interest Coverage | 7.77 | ||
| Cash Conversion | 80.59% | ||
| Profit Quality | 243.34% | ||
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.29 | ||
| Altman-Z | 3.96 |
F-Score7
WACC8.63%
ROIC/WACC1.18
Cap/Depr(3y)21.03%
Cap/Depr(5y)20.63%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.86%
EPS 3Y-10.14%
EPS 5Y-0.46%
EPS Q2Q%21.36%
EPS Next Y12.8%
EPS Next 2Y11.02%
EPS Next 3Y7.37%
EPS Next 5YN/A
Revenue 1Y (TTM)5.34%
Revenue growth 3Y1.98%
Revenue growth 5Y3.73%
Sales Q2Q%4.09%
Revenue Next Year4.17%
Revenue Next 2Y4.71%
Revenue Next 3Y4.8%
Revenue Next 5YN/A
EBIT growth 1Y18.92%
EBIT growth 3Y-8.39%
EBIT growth 5Y3.2%
EBIT Next Year18.26%
EBIT Next 3Y9.99%
EBIT Next 5YN/A
FCF growth 1Y112.26%
FCF growth 3Y5.56%
FCF growth 5Y2%
OCF growth 1Y102.82%
OCF growth 3Y5.48%
OCF growth 5Y1.88%